Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Feasibility Study on Measuring Selected Proteins in Malignant Melanoma Tissue by SRM Quantification.

Welinder, Charlotte LU ; Jönsson, Göran B LU ; Ingvar, Christian LU ; Lundgren, Lotta LU ; Baldetorp, Bo LU ; Olsson, Håkan LU orcid ; Breslin, Thomas LU ; Rezeli, Melinda ; Jansson, Bo LU and Laurell, Thomas LU , et al. (2014) In Journal of Proteome Research 13(3). p.1315-1326
Abstract
Currently there are no clinically recognized molecular biomarkers for malignant melanoma (MM) for either diagnosing disease stage or measuring response to therapy. The aim of this feasibility study was to develop targeted selected reaction monitoring (SRM) assays for identifying candidate protein biomarkers in metastatic melanoma tissue lysate. In a pilot study applying the SRM assay, the tissue expression of nine selected proteins [complement 3 (C3), T-cell surface glycoprotein CD3 epsilon chain E (CD3E), dermatopontin, minichromosome maintenance complex component (MCM4), premelanosome protein (PMEL), S100 calcium binding protein A8 (S100A8), S100 calcium binding protein A13 (S100A13), transgelin-2 and S100B] was quantified in a small... (More)
Currently there are no clinically recognized molecular biomarkers for malignant melanoma (MM) for either diagnosing disease stage or measuring response to therapy. The aim of this feasibility study was to develop targeted selected reaction monitoring (SRM) assays for identifying candidate protein biomarkers in metastatic melanoma tissue lysate. In a pilot study applying the SRM assay, the tissue expression of nine selected proteins [complement 3 (C3), T-cell surface glycoprotein CD3 epsilon chain E (CD3E), dermatopontin, minichromosome maintenance complex component (MCM4), premelanosome protein (PMEL), S100 calcium binding protein A8 (S100A8), S100 calcium binding protein A13 (S100A13), transgelin-2 and S100B] was quantified in a small cohort of metastatic malignant melanoma patients. The SRM assay was developed using a TSQ Vantage triple quadrupole mass spectrometer that generated highly accurate peptide quantification. Repeated injection of internal standards spiked into matrix showed relative standard deviation (RSD) from 6% to 15%. All nine target proteins were identified in tumor lysate digests spiked with heavy peptide standards. The multiplex SRM peptide assay panel was then measured and quantified on a set of frozen MM tissue samples obtained from the Malignant Melanoma Biobank collected in Lund, Sweden. All nine proteins could be accurately quantified using the new SRM assay format. This study provides preliminary data on the heterogeneity of biomarker expression within MM patients. The S100B protein, which is clinically used as the pathology identifier of MM, was identified in 9 out of 10 MM tissue lysates. The use of the targeted SRM assay provides potential advancements in the diagnosis of MM that can aid in future assessments of disease in melanoma patients. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Journal of Proteome Research
volume
13
issue
3
pages
1315 - 1326
publisher
The American Chemical Society (ACS)
external identifiers
  • pmid:24490776
  • wos:000332756300014
  • scopus:84896754861
  • pmid:24490776
ISSN
1535-3893
DOI
10.1021/pr400876p
language
English
LU publication?
yes
id
83567d6a-3753-4940-8d6d-8c476419e5c2 (old id 4335780)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/24490776?dopt=Abstract
date added to LUP
2016-04-01 09:58:03
date last changed
2022-03-12 00:52:57
@article{83567d6a-3753-4940-8d6d-8c476419e5c2,
  abstract     = {{Currently there are no clinically recognized molecular biomarkers for malignant melanoma (MM) for either diagnosing disease stage or measuring response to therapy. The aim of this feasibility study was to develop targeted selected reaction monitoring (SRM) assays for identifying candidate protein biomarkers in metastatic melanoma tissue lysate. In a pilot study applying the SRM assay, the tissue expression of nine selected proteins [complement 3 (C3), T-cell surface glycoprotein CD3 epsilon chain E (CD3E), dermatopontin, minichromosome maintenance complex component (MCM4), premelanosome protein (PMEL), S100 calcium binding protein A8 (S100A8), S100 calcium binding protein A13 (S100A13), transgelin-2 and S100B] was quantified in a small cohort of metastatic malignant melanoma patients. The SRM assay was developed using a TSQ Vantage triple quadrupole mass spectrometer that generated highly accurate peptide quantification. Repeated injection of internal standards spiked into matrix showed relative standard deviation (RSD) from 6% to 15%. All nine target proteins were identified in tumor lysate digests spiked with heavy peptide standards. The multiplex SRM peptide assay panel was then measured and quantified on a set of frozen MM tissue samples obtained from the Malignant Melanoma Biobank collected in Lund, Sweden. All nine proteins could be accurately quantified using the new SRM assay format. This study provides preliminary data on the heterogeneity of biomarker expression within MM patients. The S100B protein, which is clinically used as the pathology identifier of MM, was identified in 9 out of 10 MM tissue lysates. The use of the targeted SRM assay provides potential advancements in the diagnosis of MM that can aid in future assessments of disease in melanoma patients.}},
  author       = {{Welinder, Charlotte and Jönsson, Göran B and Ingvar, Christian and Lundgren, Lotta and Baldetorp, Bo and Olsson, Håkan and Breslin, Thomas and Rezeli, Melinda and Jansson, Bo and Laurell, Thomas and Fehniger, Thomas E and Wieslander, Elisabet and Pawlowski, Krzysztof and Marko-Varga, György}},
  issn         = {{1535-3893}},
  language     = {{eng}},
  number       = {{3}},
  pages        = {{1315--1326}},
  publisher    = {{The American Chemical Society (ACS)}},
  series       = {{Journal of Proteome Research}},
  title        = {{Feasibility Study on Measuring Selected Proteins in Malignant Melanoma Tissue by SRM Quantification.}},
  url          = {{http://dx.doi.org/10.1021/pr400876p}},
  doi          = {{10.1021/pr400876p}},
  volume       = {{13}},
  year         = {{2014}},
}